The Dystrophic Epidermolysis Bullosa market growth is driven by factors like increase in the prevalence of Dystrophic Epidermolysis Bullosa, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Dystrophic Epidermolysis Bullosa market report also offers comprehensive insights into the Dystrophic Epidermolysis Bullosa market size, share, Dystrophic Epidermolysis Bullosa epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Dystrophic Epidermolysis Bullosa market size growth forward.
Some of the key highlights from the Dystrophic Epidermolysis Bullosa Market Insights Report:
- Several key pharmaceutical companies, including Phoenix Tissue Repair, Castle Creek Biosciences, Phoenicis Therapeutics, Aegle Therapeutics, RHEACELL GmbH & Co. KG, Anterogen Co, Ltd, Abeona Therapeutics, Inc, InMed Pharmaceuticals, BridgeBio Inc, Eloxx Pharmaceuticals, Relief Therapeutics, Quoin Pharmaceuticals, and others, are developing novel products to improve the Dystrophic Epidermolysis Bullosa treatment outlook.
- The total Dystrophic Epidermolysis Bullosa market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
- As per DelveInsight analysis, the Dystrophic Epidermolysis Bullosa market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Dystrophic Epidermolysis Bullosa Market Landscape
Dystrophic Epidermolysis Bullosa Overview
Dystrophic epidermolysis bullosa (DEB) is the major subtype of epidermolysis bullosa (EB). EB is a group of skin diseases that cause various degrees of skin and mucous membrane fragility. The skin becomes fragile when proteins essential for skin integrity are absent, reduced, or abnormal. EB is classified into four main types and several clinical subtypes. The main classification relates to the layer of skin in which the formation of blisters occurs: EB simplex (EBS; intraepidermal layer), junctional EB (JEB; within the lamina lucida of the basement membrane), dystrophic EB (DEB; below the basement membrane), and Kindler’s EB (KEB; mixed skin cleavage pattern).
According to the National Institute of Cancer, Dystrophic Epidermolysis Bullosa is a rare inherited disorder in which blisters form on the skin and the moist inner lining of some organs and body cavities. The blisters usually appear at birth and may occur on certain body parts or all over the body, leading to scarring in the affected areas and thinning of the skin. Dystrophic Epidermolysis Bullosa comprises four major and several rare sub-types, with the three most common being intermediate dominant Dystrophic Epidermolysis Bullosa, severe recessive Dystrophic Epidermolysis Bullosa, and intermediate recessive Dystrophic Epidermolysis Bullosa.
The signs and symptoms can vary widely among affected people. In mild cases, blistering may primarily affect the hands, feet, knees, and elbows. Severe cases often involve widespread blistering, leading to vision loss, disfigurement, and other serious medical problems.
As per the National Organization for Rare Diseases, some EB occurs in an estimated 1 out of every 50,000 live births. The disorder occurs in every racial and ethnic group worldwide and affects both sexes equally.
The disease is caused by changes in the COL7A1 gene and may be inherited in an autosomal dominant or autosomal recessive manner, depending on the subtype.
Currently, no curative therapy is available. The present treatment focuses on managing symptoms and complications associated with Dystrophic Epidermolysis Bullosa. Use of non-adhesive bandages and dressings to protect the wound, moisturizers for reducing friction and itching, and medication to relieve pain are used to manage symptoms. In addition, some patients need nutritional support, supplements, occupational therapy, and/or surgery, depending on the associated features of the disease. Hence there is an urgent unmet medical need to diagnose better, treat, and possibly one day cure and eradicate this devastating disease.
Do you know the treatment paradigms for different countries? Download our Dystrophic Epidermolysis Bullosa Market Sample Report
Dystrophic Epidermolysis Bullosa Epidemiology Segmentation
DelveInsight’s Dystrophic Epidermolysis Bullosa market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Dystrophic Epidermolysis Bullosa historical patient pools and forecasted Dystrophic Epidermolysis Bullosa patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Dystrophic Epidermolysis Bullosa Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
- Dystrophic Epidermolysis Bullosa Prevalence
- Age-Specific Dystrophic Epidermolysis Bullosa Prevalence
- Gender-Specific Dystrophic Epidermolysis Bullosa Prevalence
- Diagnosed and Treatable Cases of Dystrophic Epidermolysis Bullosa
Visit for more @ Dystrophic Epidermolysis Bullosa Epidemiological Insights
Recent Breakthroughs in the Dystrophic Epidermolysis Bullosa Market
FDA Approves First Gene Therapy for Dystrophic Epidermolysis Bullosa (DEB): Vyjuvek is the first FDA-approved gene therapy for dystrophic epidermolysis bullosa (DEB) and the first topical gene therapy approved in the U.S. It’s indicated for use in patients 6 months of age or older.
Dystrophic Epidermolysis Bullosa Treatment Market
The Dystrophic Epidermolysis Bullosa market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Dystrophic Epidermolysis Bullosa market trends by analyzing the impact of current Dystrophic Epidermolysis Bullosa therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Dystrophic Epidermolysis Bullosa market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Dystrophic Epidermolysis Bullosa market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Dystrophic Epidermolysis Bullosa market in 7MM is expected to witness a major change in the study period 2019-2032.
Dystrophic Epidermolysis Bullosa Emerging Drugs
PTR-01: Phoenix Tissue Repair
Phoenix Tissue Repair is advancing an investigational therapy known as PTR-01, a systemic recombinant collagen type VII (rC7) for the treatment of Recessive Dystrophic Epidermolysis Bullosa. rC7 is a potentially disease-modifying drug that is delivered intravenously to patients, replacing defective collagen type VII with healthy collagen at the sites where it is needed both internally and externally. Phoenix Tissue Repair acquired worldwide rights to PTR-01 from Shire Plc in 2017 and has initiated its first clinical trial. Preclinical studies of PTR-01 have shown that it selectively anchors in the skin and other tissues affected by an absence of collagen type VII. In four animal models of the disease, intravenous injections of PTR-01 promoted healing of DEB wounds. These experiments have shown improvements in tissue structure, disease presentation and survival, indicating a restoration of natural skin architecture.
FCX-007: Castle Creek Biosciences
D-Fi, also known as FCX-007, (dabocemagene autoficel), is being developed as an ex vivo, autologous cell-based gene therapy to address the deficiency of functional COL7 in patients with dystrophic epidermolysis bullosa (DEB). D-Fi has been clinically studied in a Phase 1/2 clinical study (NCT02810951), which assessed 6 patients with RDEB. In this study, 80% (8/10) of treated chronic wounds demonstrated complete wound healing 12 weeks after the first injection of D-Fi, while none of the untreated wounds were healed. D-Fi was well tolerated post-administration with few reports of temporary redness or discoloration at the injection site. D-Fi is currently in Phase 3 clinical development for the localized treatment of chronic wounds in individuals with RDEB.
Dystrophic Epidermolysis Bullosa Key Companies
- Phoenix Tissue Repair
- Castle Creek Biosciences
- Phoenicis Therapeutics
- Aegle Therapeutics
- RHEACELL GmbH & Co. KG
- Anterogen Co., Ltd.
- Abeona Therapeutics, Inc
- InMed Pharmaceuticals
- BridgeBio Inc.
- Eloxx Pharmaceuticals
- Relief Therapeutics
- Quoin Pharmaceuticals
For more information, visit Dystrophic Epidermolysis Bullosa Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Dystrophic Epidermolysis Bullosa Market Report:
- 11 Years Forecast
- 7MM Coverage
- Descriptive overview of Dystrophic Epidermolysis Bullosa, causes, signs and symptoms, diagnosis, treatment
- Comprehensive insight into Dystrophic Epidermolysis Bullosa epidemiology in the 7MM
- Dystrophic Epidermolysis Bullosa marketed and emerging therapies
- Dystrophic Epidermolysis Bullosa companies
- Dystrophic Epidermolysis Bullosa market drivers and barriers
Key Questions Answered in the Dystrophic Epidermolysis Bullosa Market Report 2032:
- What was the Dystrophic Epidermolysis Bullosa market share distribution in 2019, and how would it appear in 2032?
- What is the total Dystrophic Epidermolysis Bullosa market size and the market size by therapy across the 7MM for the study period (2019-32)?
- What are the important findings from 7MM, and which country will have the greatest Dystrophic Epidermolysis Bullosa market size from 2019-32?
- During the study period (2019-2032), at what CAGR is the Dystrophic Epidermolysis Bullosa market projected to expand at 7MM?
Table of Contents:
1 Dystrophic Epidermolysis Bullosa Market Key Comprehensive Insights
2 Dystrophic Epidermolysis Bullosa Market Report Introduction
3 Competitive Intelligence Analysis for Dystrophic Epidermolysis Bullosa
4 Dystrophic Epidermolysis Bullosa Market Analysis Overview at a Glance
5 Executive Summary of Dystrophic Epidermolysis Bullosa
6 Dystrophic Epidermolysis Bullosa Epidemiology and Market Methodology
7 Dystrophic Epidermolysis Bullosa Epidemiology and Patient Population
8 Dystrophic Epidermolysis Bullosa Patient Journey
9 Dystrophic Epidermolysis Bullosa Treatment Algorithm, Dystrophic Epidermolysis Bullosa Current Treatment, and Medical Practices
10 Key Endpoints in Dystrophic Epidermolysis Bullosa Clinical Trials
11 Dystrophic Epidermolysis Bullosa Marketed Therapies
12 Dystrophic Epidermolysis Bullosa Emerging Therapies
13 Dystrophic Epidermolysis Bullosa: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Dystrophic Epidermolysis Bullosa
16 Dystrophic Epidermolysis Bullosa Market Key Opinion Leaders Reviews
18 Dystrophic Epidermolysis Bullosa Market Drivers
19 Dystrophic Epidermolysis Bullosa Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Dystrophic Epidermolysis Bullosa Epidemiology 2032
DelveInsight’s “Dystrophic Epidermolysis Bullosa – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Dystrophic Epidermolysis Bullosa epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Dystrophic Epidermolysis Bullosa Pipeline 2023
“Dystrophic Epidermolysis Bullosa Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Dystrophic Epidermolysis Bullosa market. A detailed picture of the Dystrophic Epidermolysis Bullosa pipeline landscape is provided, which includes the disease overview and Dystrophic Epidermolysis Bullosa treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/